(Q44929926)

7 December 2017

title

Primary Gleason pattern does not impact survival after permanent interstitial brachytherapy for Gleason score 7 prostate cancer (English)

1 reference

7 December 2017

1 reference

Gregory S Merrick

1

1 reference

7 December 2017

Robert W Galbreath

2

1 reference

7 December 2017

Wayne M Butler

3

1 reference

7 December 2017

Kent E Waller

4

1 reference

7 December 2017

Zachariah A Allen

5

1 reference

7 December 2017

Jonathan Lief

6

1 reference

7 December 2017

Edward Adamovich

7

1 reference

7 December 2017

language of work or name

English

0 references

publication date

1 July 2007

1 reference

7 December 2017

1 reference

7 December 2017

volume

110

1 reference

7 December 2017

issue

2

1 reference

7 December 2017

page(s)

289-296

1 reference

Primary Gleason pattern as a predictor of disease progression in gleason score 7 prostate cancer: a multivariate analysis of 823 men treated with radical prostatectomy

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22793

7 January 2021

Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22793

7 January 2021

Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22793

7 January 2021

Gleason score 7 prostate cancer: a heterogeneous entity? Correlation with pathologic parameters and disease-free survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22793

7 January 2021

The impact of the biopsy Gleason score on PSA outcome for prostate cancer patients with PSA < or = 10 ng/ml and T1c,2a: implications for patient selection for prostate-only therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22793

7 January 2021

The impact of primary Gleason grade on biochemical outcome following brachytherapy for hormone-naive Gleason score 7 prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22793

7 January 2021

Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: impact on prostate cancer specific survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22793

7 January 2021

Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22793

7 January 2021

Should Gleason score 7 prostate cancer be considered a unique grade category?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22793

7 January 2021

Clinical significance of biopsy-derived primary Gleason score among radical prostatectomy candidates with Gleason 7 tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22793

7 January 2021

Impact of the percentage of positive biopsy cores on the further stratification of primary grade 3 and grade 4 Gleason score 7 tumors in radical prostatectomy patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22793

7 January 2021

The prognostic significance of Gleason Grade in patients treated with permanent prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22793

7 January 2021

Outcome and predictive factors for patients with Gleason score 7 prostate carcinoma treated with three-dimensional conformal external beam radiation therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22793

7 January 2021

Extracapsular Radiation Dose Distribution After Permanent Prostate Brachytherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22793

7 January 2021

Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22793

7 January 2021

Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22793

7 January 2021

Influence of body mass index on biochemical outcome after permanent prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22793

7 January 2021

Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22793

7 January 2021

High-grade carcinoma of the prostate: a comparison of current local therapies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22793

7 January 2021

Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22793

7 January 2021

Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22793

7 January 2021

A prostate gland volume of more than 75 cm3 predicts for a favorable outcome after radical prostatectomy for localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22793

7 January 2021

Is Biopsy Gleason Score Independently Associated With Biochemical Progression Following Radical Prostatectomy After Adjusting for Pathological Gleason Score?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22793

7 January 2021

20 Gy versus 44 Gy supplemental beam radiation with Pd-103 prostate brachytherapy: preliminary biochemical outcomes from a prospective randomized multi-center trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22793

7 January 2021

Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22793

7 January 2021

Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22793

7 January 2021

Step-by-step lifestyle changes that can improve urologic health in men, part I: What do I tell my patients?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22793

7 January 2021

Step-by-step lifestyle changes that can improve urologic health in men, part II: What do I tell my patients?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22793

7 January 2021

Identifiers

DOI

10.1002/CNCR.22793

1 reference

7 December 2017

1 reference